Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robin Foà

Showing results (11-20 of 526) with videos related to

Pageof 53
Sort By:
The Lancet. Oncology|October 1, 2011
Caring for patients with haematological malignanciesRobin Foà, Ulrich Jaeger
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|November 1, 2016
How has the management of Ph<sup>+</sup> acute lymphoblastic leukemia (ALL) changed over the yearsSabina Chiaretti, Robin Foà
Mediterranean Journal of Hematology and Infectious Diseases|March 13, 2019
Relapsed/Refractory Chronic Lymphocytic Leukemia: Chemoimmunotherapy, Treatment until Progression with Mechanism-Driven Agents or Finite-Duration Therapy?Antonio Cuneo, Robin Foà
The New England Journal of Medicine|June 22, 2022
Philadelphia Chromosome-Positive Acute Lymphoblastic LeukemiaRobin Foà, Sabina Chiaretti
Hematology. American Society of Hematology. Education Program|December 6, 2015
Management of adult Ph-positive acute lymphoblastic leukemiaSabina Chiaretti, Robin Foà
Current Oncology Reports|March 8, 2018
Current Information and Recommendations on the Discontinuation of TKI Inhibitors in Chronic Myeloid LeukemiaMassimo Breccia, Robin Foà
The Lancet. Haematology|January 25, 2020
First-line dasatinib discontinuation in chronic myeloid leukaemia: another step towards an "operational cure"Massimo Breccia, Robin Foà
The New England Journal of Medicine|June 21, 2013
A mechanism-driven treatment for chronic lymphocytic leukemia?Robin Foà, Anna Guarini
Expert Review of Hematology|December 22, 2018
Intravenous arsenic trioxide and all-trans retinoic acid as front-line therapy for low-risk acute promyelocytic leukemiaMassimo Breccia, Robin Foà
European Journal of Internal Medicine|December 12, 2018
Chemotherapy-free and reduced intensity approaches in elderly patients with B-lineage acute lymphoblastic leukemiaSabina Chiaretti, Robin Foà
Pageof 53

Showing results (11-20 of 526) with videos related to

Sort By:
Pageof 53
The Lancet. Oncology|October 1, 2011
Caring for patients with haematological malignanciesRobin Foà, Ulrich Jaeger
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|November 1, 2016
How has the management of Ph<sup>+</sup> acute lymphoblastic leukemia (ALL) changed over the yearsSabina Chiaretti, Robin Foà
Mediterranean Journal of Hematology and Infectious Diseases|March 13, 2019
Relapsed/Refractory Chronic Lymphocytic Leukemia: Chemoimmunotherapy, Treatment until Progression with Mechanism-Driven Agents or Finite-Duration Therapy?Antonio Cuneo, Robin Foà
The New England Journal of Medicine|June 22, 2022
Philadelphia Chromosome-Positive Acute Lymphoblastic LeukemiaRobin Foà, Sabina Chiaretti
Hematology. American Society of Hematology. Education Program|December 6, 2015
Management of adult Ph-positive acute lymphoblastic leukemiaSabina Chiaretti, Robin Foà
Current Oncology Reports|March 8, 2018
Current Information and Recommendations on the Discontinuation of TKI Inhibitors in Chronic Myeloid LeukemiaMassimo Breccia, Robin Foà
The Lancet. Haematology|January 25, 2020
First-line dasatinib discontinuation in chronic myeloid leukaemia: another step towards an "operational cure"Massimo Breccia, Robin Foà
The New England Journal of Medicine|June 21, 2013
A mechanism-driven treatment for chronic lymphocytic leukemia?Robin Foà, Anna Guarini
Expert Review of Hematology|December 22, 2018
Intravenous arsenic trioxide and all-trans retinoic acid as front-line therapy for low-risk acute promyelocytic leukemiaMassimo Breccia, Robin Foà
European Journal of Internal Medicine|December 12, 2018
Chemotherapy-free and reduced intensity approaches in elderly patients with B-lineage acute lymphoblastic leukemiaSabina Chiaretti, Robin Foà
Pageof 53